Zhang Y, Wang Y, Zhao G, Orsulic S, Matei D. Metabolic dependencies and targets in ovarian cancer. Pharmacol Ther. 2023;245: 108413.

Article  CAS  PubMed  Google Scholar 

Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fucikova J, Palova-Jelinkova L, Klapp V, Holicek P, Lanickova T, Kasikova L, Drozenova J, Cibula D, Alvarez-Abril B, Garcia-Martinez E, et al. Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends Cancer. 2022;8(5):426–44.

Article  CAS  PubMed  Google Scholar 

Imyanitov E, Sokolenko A. Integrative genomic tests in clinical oncology. Int J Mol Sci. 2022;23(21):13129.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmad E, Ali A, Nimisha AK, Sharma FA, Dar GM, Singh AM, Apurva AK, Athar A, Parveen F, Mahajan B, Saluja SS, et al. Molecular approaches in cancer. Clin Chim Acta. 2022;537:60–73.

Article  CAS  PubMed  Google Scholar 

Feng Z, Shao D, Cai Y, Bi R, Ju X, Chen D, Song C, Chen X, Li J, An N, et al. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. J Ovarian Res. 2023;16(1):53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective. Eur J Cancer. 2023;179:136–46.

Article  CAS  PubMed  Google Scholar 

Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, Zheng H, Liu J, Wu X, Wang L, et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023. https://doi.org/10.1001/jamaoncol.2023.2283.

Article  PubMed  PubMed Central  Google Scholar 

Lheureux S, Prokopec SD, Oldfield LE, Gonzalez-Ochoa E, Bruce JP, Wong D, Danesh A, Torti D, Torchia J, Fortuna A, et al. Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a phase II trial of cediranib plus olaparib for ovarian cancer at time of PARP inhibitor progression. Clin Cancer Res. 2023;29:3706.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer. 2022;22(11):640–56.

Article  CAS  PubMed  Google Scholar 

Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16(6):475.

Article  PubMed  PubMed Central  Google Scholar 

Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, Wauters E, Pomella V, Verbandt S, Busschaert P, et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30(9):745–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.

Article  PubMed  PubMed Central  Google Scholar 

Miao YR, Xia M, Luo M, Luo T, Yang M, Guo AY. ImmuCellAI-mouse: a tool for comprehensive prediction of mouse immune cell abundance and immune microenvironment depiction. Bioinformatics. 2022;38(3):785–91.

Article  CAS  PubMed  Google Scholar 

Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, Vilo J. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021;385(23):2123–31.

Article  PubMed  Google Scholar 

Pawlowska A, Rekowska A, Kurylo W, Panczyszyn A, Kotarski J, Wertel I. Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241310859.

Article  PubMed  PubMed Central  Google Scholar 

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.

Article  PubMed  Google Scholar 

Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10271):281–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gourley C, Balmana J, Ledermann JA, Serra V, Dent R, Loibl S, Pujade-Lauraine E, Boulton SJ. Moving from poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 2019;37(25):2257–69.

Article  CAS  PubMed  Google Scholar 

Watanabe TK, Shimizu F, Nagata M, Takaichi A, Fujiwara T, Nakamura Y, Takahashi E, Hirai Y. Cloning, expression pattern and mapping to 12p 13.2 –> p13.1 of CLAPS3, a gene encoding a novel clathrin-adaptor small chain. Cytogenet Cell Genet. 1996;73(3):214–7.

Article  CAS  PubMed  Google Scholar 

Qian C, Jiang Z, Zhou T, Wu T, Zhang Y, Huang J, Ouyang J, Dong Z, Wu G, Cao J. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma. Front Immunol. 2022;13:1034992.

Article  PubMed  PubMed Central  Google Scholar 

Wu G, Chen M, Ren H, Sha X, He M, Ren K, Qi J, Lin F. AP3S1 is a novel prognostic biomarker and correlated with an immunosuppressive tumor microenvironment in pan-cancer. Front Cell Dev Biol. 2022;10: 930933.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Guo Y, Xiao M, Zhang W. The immune escape mechanism of nasopharyngeal carcinoma. FASEB J. 2023;37(7): e23055.

Article  CAS  PubMed  Google Scholar 

Tiwari A, Oravecz T, Dillon LA, Italiano A, Audoly L, Fridman WH, Clifton GT. Towards a consensus definition of immune exclusion in cancer. Front Immunol. 2023;14:1084887.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aguilar-Cazares D, Chavez-Dominguez R, Marroquin-Mucino M, Perez-Medina M, Benito-Lopez JJ, Camarena A, Rumbo-Nava U, Lopez-Gonzalez JS. The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. Front Endocrinol. 2022;13: 929572.

Article  Google Scholar 

Miro C, Di Giovanni A, Murolo M, Cicatiello AG, Nappi A, Sagliocchi S, Di Cicco E, Morra F, Celetti A, Pacifico F, et al. Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer. Cancer Lett. 2022;532: 215581.

Article  CAS  PubMed  Google Scholar 

Liotti A, La Civita E, Cennamo M, Crocetto F, Ferro M, Guadagno E, Insabato L, Imbimbo C, Palmieri A, Mirone V, et al. Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform. Prostate. 2021;81(7):407–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Truxova I, Cibula D, Spisek R, Fucikova J. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. J Immunother Cancer. 2023;11(2):005968.

Article  Google Scholar 

Dumitru A, Dobrica EC, Croitoru A, Cretoiu SM, Gaspar BS. Focus on PD-1/PD-L1 as a therapeutic target in ovarian cancer. Int J Mol Sci. 2022;23(20):12067.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2021;77:127–43.

Article  PubMed  Google Scholar 

Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science. 2023;380(6649):eabo2296.

Article  CAS  PubMed  Google Scholar 

Ding Z, Quast I, Yan F, Liao Y, Pitt C. CD137 L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy. Immunol Cell Biol. 2022;100(9):705–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brightman SE, Becker A, Thota RR, Naradikian MS, Chihab L, Zavala KS